3'-Sialyllactose_SYNAURA_SYNAURA,HMO supplier,HMOs,Human Milk Oligosaccharides,2'-FL,LNnT,3'-SL, infant formula ingredient, nutritional raw material

中文

3'-Sialyllactose（3'-SL）

Human Milk Oligosaccharides（HMOs）

Human milk oligosaccharides (HMOs) are the third largest solid component in breast milk and the largest active nutrient. Currently, more than 200 HMOs have been identified. Since oligosaccharides chains can be fucosylated or sialylated, they are usually divided into three categories：

（a）Fucosylated neutral HMO(35-50%)

（b）Nonfucosylated neutral HMO (42-55%)

（c）Sialylated HMO (12-14%)

Representative compounds of Sialylated HMO——3'-Sialyllactose（3'-SL）

It is one of the most important representative substances of Sialylated HMO and the main carrier of sialic acid in breast milk

It is the most extensively and deeply studied type of HMOs in the fields of brain development and neurocognition

It has potential new advantages such as metabolic health, cardiovascular health and bone health.

Synaura HMOs Product Advantages

Pioneer in International Certification

——3′-Sialyllactose (3′-SL) approved by the U.S. self-GRAS certification

Global leading patents layout

——A total of 50+ domestic and international patent applications, with 30+ patents granted to date. Patents

covering HMO strain development, process optimization, testing, and application, establish an independent

original research and development patent system.

Reference

1. Rousseaux, A., et al. (2021). Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents. Frontiers in Immunology, 12, Article 801911.

2. 3′-Sialyllactose. PubChem; National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/123914 (accessed 2025-09-01).

3. Jeon, J., et al. (2017). 3'-Sialyllactose protects against osteoarthritic development by facilitating cartilage homeostasis. Journal of Biological Chemistry, 22(1):57-66.

4. Zhu, M., et al. (2025). Potential effects of sialic acid and 3'-Sialyllactose on intestinal health and anti-cardiovascular disease in mice fed with a high-fat diet. Journal of Functional Foods, 106215.

5. *The certification results are sourced from third-party organizations, including the《2025 Certificate of Conformity Verification》and the《2023 2'-FL Chemical Structural Equivalence Experiment》; the analytical data is sourced from the GRAS application data submitted by various companies.

China Headquarters

Xiaowei Zhang:+86-13910088419(WeChat)

Wenqiang Wang:+86-13811202192(WeChat)

GLOBAL OFFICE

Xiaowei ZHANG: +86-13910088419(WeChat)

Xinhui LI: +86-18241587387(WeChat)

Official email

service@synaura.cn

Company Address

Floors 1-2, Building 2, Lane 500, Furonghua Road, Pudong New Area, Shanghai

沪ICP备2024048832号-1